Why Your Rheumatologist Changed Your Plaquenil Dose: the Weight-Based Rule Explained
Your Plaquenil Dose and Your Eyes at a Glance
Your dose changed because the safety rule changed, not because your eyes got worse. Most people given a new number feel exactly the same the next day.
Plaquenil is a brand of hydroxychloroquine. It is now dosed against your body weight. The prescribing information states that daily doses above 5 mg/kg of actual body weight increase how often damage to the retina (clinical: retinopathy) occurs.1 The retina is the light-sensing layer at the back of your eye.
The stakes are real, and the odds are good at the lower number. Among long-term users dosed at 5 mg/kg a day or less, about 3 of every 100 had retinopathy by 15 years, compared with about 22 of every 100 dosed above 6 mg/kg a day.2
You do not need to do anything today except take the dose you were given. Then check when your next eye screening is due.
The rule is a ceiling, not a target. Your daily milligrams should sit at or under five times your weight in kilograms, using the weight you actually are rather than a calculated figure.
The 2016 revision of the eye screening guidance recommended setting that ceiling from real body weight, which correlates better with risk than ideal weight.3 That one change is why two patients of the same height can now be given different pill counts.
Nothing in the rule says the drug stopped working, and nothing in it says your old dose harmed you.
Three practical steps cover almost everyone here.
- Write down your current weight and your new daily milligrams, and take both to your next appointment.
- Find out when your last eye screening for this drug was, or whether you have had one.
- Ask your prescriber what weight they used and why, especially if yours has moved a lot.
Your dose belongs to your prescriber, and your screening schedule to your eye doctor.
What Hydroxychloroquine Is and Why It Has a Ceiling at All
Hydroxychloroquine is a long-term control drug, not a painkiller. It works in the background to keep autoimmune disease from flaring, which is why rheumatologists are reluctant to give it up.
In a 24-week randomized trial in 47 people with stable systemic lupus, 16 of 22 who were switched to placebo had a clinical flare, compared with 9 of 25 who stayed on hydroxychloroquine.4 That is why the conversation is about adjusting your dose rather than dropping the drug.
Over years of use, a small amount of the drug settles in the retina, and in some people it injures the cells there. Advanced retinopathy from this drug can progress despite stopping the medicine, and it is not reversible to any significant degree.5 The label instructs prescribers to stop the drug if eye toxicity is suspected, since retinal changes may progress even after treatment ends.1
Hold that next to the other half of the picture. In a cohort of 3,325 long-term users, most of the retinopathy that screening identified was mild.2 Finding it at that stage is what the screening schedule is for.
Among 2,361 people who had taken the drug for at least five years, about 7 or 8 of every 100 had retinopathy when sensitive testing was used.6 In a separate group of 310 Korean patients, retinopathy was found in about 3 of every 100 overall, and about 5 of every 100 among those on the drug five years or longer.7
Both groups were long-term users, and risk builds with years on the drug. That is why screening tightens after five years.
Real Weight Versus Ideal Weight: What Actually Changed
The 2011 screening recommendation accepted the routine 400 mg daily dose for most patients, and said the dose should be determined on the basis of ideal body weight for individuals of short stature, to avoid overdosage.8 Ideal body weight is a formula figure derived from height, not a measurement.
That was reasonable with the evidence then. It did not hold up in larger patient groups.
Bigger datasets showed which weight figure actually lined up with who developed damage. The prescribing information now names daily dosages at or above 5 mg/kg of actual body weight among the risk factors for retinal damage.1
For a taller or heavier person the arithmetic can allow the same 400 mg as before. For a smaller person it often lands lower, and that is whose prescription changed.
Because the ceiling is 5 mg per kilogram of actual body weight, five times your weight in kilograms gives your daily ceiling in milligrams.1 A person of about 50 kg lands near 250 mg, a person of about 60 kg near 300 mg, a person of about 70 kg near 350 mg, and a person of about 80 kg near 400 mg.
| If you weigh about | Five times that weight is about |
|---|---|
| 50 kg (110 pounds) | 250 mg a day |
| 60 kg (132 pounds) | 300 mg a day |
| 70 kg (154 pounds) | 350 mg a day |
| 80 kg (176 pounds) | 400 mg a day |
This table is arithmetic, not a prescription. The labeled long-term dose for rheumatoid arthritis and lupus runs from 200 mg to 400 mg a day, so the number does not simply keep climbing with weight.1 Your disease activity, kidney function, and other medicines count too.
Taking the New Dose Day to Day
Consistency matters more than the hour. The label directs that the tablets be taken by mouth with food or milk.1 Attach the dose to one fixed anchor in your day.
Available tablet strengths do not divide neatly into a ceiling like 350 mg, so prescribers handle the gap in one of two ordinary ways. Neither is a compromise.
One is an alternating pattern, such as 400 mg on some days and 200 mg on others, so the weekly average lands under the ceiling. The other is a split tablet, which only works if the product you are dispensed divides reliably. Your pharmacist can check that.
Cutting the dose further than you were told, or skipping days to stretch a prescription, carries its own cost. In an international cohort of 1,460 people who started hydroxychloroquine, those who reduced or stopped the drug had a higher rate of lupus flare than those who stayed on their dose.9
Specialty societies agree the drug need not be stopped until the evidence for retinopathy is definitive, particularly in patients with active rheumatic or skin disease.10 If the new dose is not controlling your symptoms, report it rather than self-correcting.
Do not judge the change in a week. The label notes that the action of hydroxychloroquine is cumulative and may require weeks to months for maximum effect.1 Give it a couple of months, note your joint or skin symptoms, and bring that to your follow-up.
Side Effects: the Everyday Ones and the Eye Ones
Most side effects on this drug are digestive. The most common adverse reactions reported with hydroxychloroquine sulfate are nausea, vomiting, diarrhea, and abdominal pain.1 Mention them at your next visit if they persist, since a change in timing often helps.
The eye side effect is the one the dose rule exists for, and it is silent at the stage screening is designed to catch. Most patients who develop toxicity from this drug have no visual symptoms at all.5
That is not a reason for alarm between appointments. It is why the appointments are scheduled rather than triggered by symptoms.
Screening does the heavy lifting, but a few changes are worth mentioning to both offices before the annual visit.
- Words or letters that fade or drop out when you read a well-lit page.
- A dim or blank patch just beside what you are looking at.
- Colors that look washed out.
- Needing much more light to read than a year ago.
Any of these can also come from ordinary causes, so reporting one asks for an appointment rather than signalling that something is wrong.
Who Needs a Lower Dose or Closer Watching
Kidney disease and concurrent tamoxifen use were each associated with higher odds of retinopathy in the 2,361-patient study.6 The label names duration of treatment beyond five years, renal impairment, and use of concomitant medicines such as tamoxifen citrate among the risk factors for retinal damage.1
If either applies to you, say so at both offices. That detail travels badly between charts.
The formal barrier is narrow. The label lists hydroxychloroquine as contraindicated in people with known hypersensitivity to 4-aminoquinoline compounds.1
Beyond that, existing eye disease and other medicines are usually handled by adjusting the dose and screening interval, not by ruling the drug out.
Current screening guidance names underlying retinal or macular disease, older age at the start of therapy, and prolonged duration of use among the factors that raise risk.5 If you already have macular degeneration or another retinal condition, your eye doctor may want shorter intervals.
What the Long-Term Numbers Actually Look Like
The figure most people want is for someone dosed correctly over decades. In a cohort of 3,325 long-term users, retinopathy had appeared in about 3 of every 100 people dosed at 5 mg/kg a day or less by the 15-year mark.2 That is the band the ceiling is meant to keep people in.
The gap between dose bands is what makes the rule worth the inconvenience. In that same cohort, the 15-year figure was about 11 of every 100 at 5 to 6 mg/kg a day, and about 22 of every 100 above 6 mg/kg a day.2 A change that looks small on paper moves you between those bands.
Screening does not lower your risk of damage. It changes how much exists by the time anyone knows. In that cohort, retinopathy had appeared in about 3 of every 100 by 10 years and about 9 of every 100 by 15 years.2
Screening: What Your Eye Doctor Checks and When
Everyone starting this drug needs a starting-line record of the retina, so later scans have something to be measured against. The label recommends a baseline eye examination within the first year of starting the drug, including best corrected distance visual acuity, an automated visual field test of the central 10 degrees, and a scan of the retina (clinical: spectral domain optical coherence tomography).1
The scan takes a few minutes and involves no needles.
The rheumatology, dermatology and ophthalmology societies agreed that screening after the baseline exam may be deferred for five years, and after that should be done every year, absent special risk factors.10 Current Academy guidance likewise starts annual screening after the first five years, and starts it sooner when risk factors are present.5
Screening correctly is the responsibility of the ophthalmologist or other eye care professional.10 In practice that means an optometrist or an ophthalmologist.
Two kinds of test do the work. One photographs the structure of the retina, the other measures what it can still see. Current guidance treats optical coherence tomography of the macula and wide-pattern fundus autofluorescence as the primary screening tests, with automated visual fields and multifocal electroretinography used to confirm findings.5
Together they answer two different questions: whether the retina looks damaged, and whether it still works.
The damage does not appear in the same place in everyone. Asian patients often show an extramacular pattern of damage, further from the center of vision than the usual parafoveal pattern.3 A pericentral or mixed pattern was more common among 310 Korean patients than in reported white populations.7
If your eye doctor orders a 24-2 or 30-2 field instead of the narrower 10-2, this is usually why.
Working With Your Rheumatologist and Your Eye Doctor Together
Two offices share this drug, and each owns a different half. The societies state that the prescriber is responsible for prescribing hydroxychloroquine properly, the eye care professional for screening correctly, and both for advising the patient.10
So dose questions go to the prescriber, scan questions to the eye doctor.
Book an eye appointment sooner than your yearly one, and tell your prescriber at the same time, if any of the vision changes listed earlier appear or persist.
Also get in touch if your weight changes substantially, if you are started on tamoxifen, or if your kidney function drops. Each can shift your dose ceiling or your screening interval, and neither office will know unless someone tells them.
Bring your current weight, your exact daily milligrams including any alternating pattern, the month and year you started the drug, and the dates of previous eye scans. Add your medicine list, with tamoxifen and any kidney diagnosis called out.
Questions Patients Ask About the New Plaquenil Dose Rule
Because the rule changed, not your body. Older guidance let prescribers work from a calculated ideal weight derived from height. The current ceiling uses the weight you actually are. The 2016 revision recommended real body weight, which correlates better with risk than ideal weight.3 For a smaller-framed person that swap often produces a lower daily number, even though nothing about your health has changed.
It might, and that is worth watching rather than assuming. The drug does hold disease activity down: in a randomized trial in stable lupus, 16 of 22 people moved to placebo flared, compared with 9 of 25 who stayed on the drug.4 A modest reduction is not the same as stopping, and most people notice nothing. Keep a symptom note for two months and bring it to your follow-up.
Raise it, and let your prescriber do the arithmetic with you. The prescribing information names daily doses above 5 mg/kg of actual body weight as a risk factor for retinal damage.1 At 70 kg, five times your weight is 350 mg, so 400 mg sits above that ceiling. It does not follow that your dose is wrong for you, since disease activity counts too. It does make the question a fair one to ask.
Ask your pharmacist before you cut anything. Whether a tablet divides reliably depends on the product you are dispensed, and an unevenly split tablet gives you an uneven dose day to day. The usual alternative is an alternating pattern, one strength on some days and another on the rest. Either way, the pattern belongs in the prescription.
Not reversible in the sense of healing back. Advanced retinopathy from this drug can progress despite stopping the medicine, and is not reversible to any significant degree.5 What early detection changes is how much damage exists when the drug is adjusted. Most of the retinopathy identified in a 3,325-person screened cohort was mild.2 That is the stage screening aims at.
Yes. The ceiling lowers risk but does not remove it, and risk still builds with years of use. In a cohort of 3,325 long-term users, about 3 of every 100 dosed at 5 mg/kg a day or less had retinopathy by 15 years.2 That is a small number, and it is not zero. Screening makes it likelier damage is found on a scan than noticed while reading.
More Questions About Dosing, Screening, and Staying on the Drug
Most people at twelve years have not been, and you are in the window where screening matters most. Among 2,361 patients who had used the drug at least five years, about 7 or 8 of every 100 had retinopathy on sensitive testing.6 If you have never had a dedicated scan for this drug, arranging one is the useful next step. Bring your start date and dose history so the interval can be judged.
Because the damage does not always appear in the same place. Asian patients often show an extramacular pattern of damage rather than the usual parafoveal one.3 A narrow 10-2 field looks only at the central zone, so a wider 24-2 or 30-2 pattern is used when damage is likelier to sit further out. Your background and your earlier scans guide which pattern is ordered.
Your ceiling moves with you, so the dose is worth revisiting. A ceiling built on real body weight is only as current as the weight it was calculated from, so a substantial change in either direction is worth a message to your prescriber. Weight loss matters most: a dose that sat under the ceiling at your old weight can end up above it with nothing else changing.
That decision belongs with your rheumatologist, and the evidence argues against doing it casually. In an inception cohort of 1,460 people who started hydroxychloroquine, those who reduced or stopped it had a higher rate of lupus flare than those who maintained their dose.9 Specialty societies also advise that the drug need not be stopped until evidence of retinopathy is definitive, especially with active disease.10 Raise the question rather than acting on it.
- What is my daily dose now, and what weight was it calculated from?
- Does my kidney function or any medicine change my ceiling or screening interval?
- Have I had a baseline retinal scan, and when is my next screening due?
- Which visual field pattern is right for me, and why that one?
- If my symptoms worsen on the new dose, what is the plan?
- Who sends my eye results to my rheumatologist?
- U.S. Food and Drug Administration, via DailyMed (2026). Hydroxychloroquine Sulfate Tablets, for oral use: full prescribing information (revised 3/2026).
- Melles RB, Jorge AM, Marmor MF, et al. Annals of Internal Medicine (2023). Hydroxychloroquine Dose and Risk for Incident Retinopathy: A Cohort Study.
- Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF. Ophthalmology (2016). Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
- The Canadian Hydroxychloroquine Study Group. New England Journal of Medicine (1991). A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.
- American Academy of Ophthalmology clinical statement (2026). Recommendations on Screening for Hydroxychloroquine Retinopathy (2026 revision).
- Melles RB, Marmor MF. JAMA Ophthalmology (2014). The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.
- Journal of Korean Medical Science (2017). Frequency and Clinical Characteristics of Hydroxychloroquine Retinopathy in Korean Patients with Rheumatologic Diseases.
- Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Ophthalmology (2011). Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy.
- Annals of the Rheumatic Diseases (2021). Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
- American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society and American Academy of Ophthalmology, via AAO (2021). ACR, AAD, RDS, and AAO 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity.